Phase I study of single-agent pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with ErbB2+metastatic breast cancer

被引：1
|
作者：
Xu, B.
Ma, F.
Chen, S.
Li, Q.
Yang, F.
Zhang, Y.
Chen, X.
Zhong, D.
Zhang, G.
机构：
[1] Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China
[2] Chinese Acad Sci, Inst Mat Med, Shanghai, Peoples R China
[3] Jiangsu Hengrui Med Co LTD, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P4-14-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-14-18
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients
    David A. Reardon
    Charles A. Conrad
    Timothy Cloughesy
    Michael D. Prados
    Henry S. Friedman
    Kenneth D. Aldape
    Paul Mischel
    Jane Xia
    Clifford DiLea
    Jerry Huang
    William Mietlowski
    Margaret Dugan
    Wei Chen
    W. K. Alfred Yung
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1507 - 1518
  • [42] Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients
    Reardon, David A.
    Conrad, Charles A.
    Cloughesy, Timothy
    Prados, Michael D.
    Friedman, Henry S.
    Aldape, Kenneth D.
    Mischel, Paul
    Xia, Jane
    DiLea, CliVord
    Huang, Jerry
    Mietlowski, William
    Dugan, Margaret
    Chen, Wei
    Yung, W. K. Alfred
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1507 - 1518
  • [43] The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer
    Bao, Kelvin K. H.
    Sutanto, Leone
    Tse, Shirley S. W.
    Man Cheung, Ka
    Chan, Jeffrey C. H.
    JAMA NETWORK OPEN, 2021, 4 (11)
  • [44] HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
    Wang, Y.
    Jiang, T.
    Qin, Z.
    Jiang, J.
    Wang, Q.
    Yang, S.
    Rivard, C.
    Gao, G.
    Ng, T. L.
    Tu, M. M.
    Yu, H.
    Ji, H.
    Zhou, C.
    Ren, S.
    Zhang, J.
    Bunn, P.
    Doebele, R. C.
    Camidge, D. R.
    Hirsch, F. R.
    ANNALS OF ONCOLOGY, 2019, 30 (03) : 447 - 455
  • [45] Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer
    Saip, P.
    Eralp, Y.
    Ozkan, M.
    Karaca, H.
    Benekli, M.
    Cetin, B.
    Isikdogan, A.
    Kucukoner, M.
    Basaran, G.
    Sen, F.
    Un, O.
    Onur, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] A potential for combining the mTOR inhibitor RAD001 (everolimus) with the ErbB2 receptor tyrosine kinase inhibitory antibody trastuzumab in breast cancer
    Lane, H.
    Stephan, C.
    Zumstein-Mecker, S.
    Welsch, A.
    Tinetto, W.
    Klopfenstein, M.
    Chateny-Rivauday, C.
    O'Reilly, T.
    Hynes, N.
    Baselga, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 175 - 175
  • [47] ARRY-334543 in ErbB2 positive metastatic breast cancer and other ErbB expressing-cancers: experience from expansion cohorts on a phase I study
    Ellard, Susan
    Rothenberg, Mace
    Cohen, Roger
    Taylor, Marianne
    Hartt, Nancy
    Berlin, Jordan
    Murphy, Patricia
    Kollmannsberger, Christian
    Maloney, Lara
    Ptaszynski, Mieke
    Gelmon, Karen
    CANCER RESEARCH, 2009, 69
  • [48] A single-institution experience from the Lapatinib Expanded Access Program - effect of lapatinib and capecitabine combination therapy on CNS metastases in patients with ErbB2+metastatic breast cancer
    Kaufman, B.
    Weitzen, R.
    Goldfarb, A.
    Ephrat, N.
    Kuchuk, I.
    Golan, T.
    Wolf, I.
    Elia, R.
    EJC SUPPLEMENTS, 2008, 6 (07): : 175 - 175
  • [49] A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
    Lin, Nancy U.
    Winer, Eric P.
    Wheatley, Duncan
    Carey, Lisa A.
    Houston, Stephen
    Mendelson, David
    Munster, Pamela
    Frakes, Laurie
    Kelly, Steve
    Garcia, Agustin A.
    Cleator, Susan
    Uttenreuther-Fischer, Martina
    Jones, Hilary
    Wind, Sven
    Vinisko, Richard
    Hickish, Tamas
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) : 1057 - 1065
  • [50] A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
    Nancy U. Lin
    Eric P. Winer
    Duncan Wheatley
    Lisa A. Carey
    Stephen Houston
    David Mendelson
    Pamela Munster
    Laurie Frakes
    Steve Kelly
    Agustin A. Garcia
    Susan Cleator
    Martina Uttenreuther-Fischer
    Hilary Jones
    Sven Wind
    Richard Vinisko
    Tamas Hickish
    Breast Cancer Research and Treatment, 2012, 133 : 1057 - 1065
12345